Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 11, 2011

View Archived Issues

Eisai's Halaven injection approved in Singapore for metastatic breast cancer

Cardiac imaging using [123I]-mIBG can predict development of permanent atrial fibrillation

Dextran-coated iron oxide nanoparticles detect cholera enterotoxin with high sensitivity

Homocysteine level in serum is a biomarker for extent of vitiligo

Aptamer-targeted nanoparticle-encapsulated cisplatin prodrug shows promise in vivo

New inverse agonist of RAR-related orphan receptor-alpha SR-3335 improves glucose homeostasis

BioAlliance Pharma reports preliminary data from survey in patients with herpes labialis

PolyMedix begins phase II trial of PMX-60056 for reversal of heparin action in surgical setting

Teva Pharma reports phase III data on Qnaze in perennial allergic rhinitis

Novel urotensin UT receptor antagonists claimed by sanofi-aventis

CeNeRx presents first-in-human results on CXB-909

Cytokinetics and Amgen divulge design of phase IIb trial of intravenous omecamtiv mecarbil

Cephalon and Alba Therapeutics enter option agreement for larazotide acetate

GeoVax opens second site for ongoing HIV vaccine trial

First patient treated in CMV-ACE/ASPECT trial of preemptive cell therapy for CMV infection

Amicus Therapeutics begins phase II trial of Amigal plus ERT in Fabry's disease

European orphan drug status recommended for QLT-091001 in LCA and RP

Evotec enters definitive agreement to acquire Kinaxo Biotechnologies

Anacor and Medicis to collaborate on development of acne treatments

Futura Medical and Ansell enter commercialization agreement for PET-500

Eisai and Bial launch antiepileptic Zebinix in Spain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
AI drug developer Insilico to raise $292 million in Hong Kong IPO
BioWorld
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...